GLP-1s for endometriosis and PCOS: promising or overhyped?

What did @ditto.daily actually say?

Here's the awkward part: the transcript attached to this video is song lyrics, not health commentary. There is no spoken medical content to directly quote. The caption, however, makes several specific claims worth examining: that GLP-1 receptor agonists have functions "directly in our brain, our reproductive system, and in reducing inflammation," and that research applying them to endometriosis and PCOS is "really promising." We're fact-checking the caption's claims because that's what 1.3 million viewers read alongside whatever audio was playing.

The caption cuts off mid-sentence, which is a small but real problem. Incomplete claims leave audiences to fill in blanks, and in a medical context, that's where misunderstanding starts. That said, the substantive claims in the caption are specific enough to evaluate against the published literature.

Does the science back this up?

Mostly, yes, with important caveats about how far "promising" actually gets us clinically. GLP-1 receptors are expressed in the brain, ovaries, and uterus, and semaglutide has documented anti-inflammatory effects in preclinical and some clinical settings. But "promising research" and "proven treatment" are not the same thing.

On the brain: GLP-1 receptors in the hypothalamus regulate appetite, stress response, and mood, and there is legitimate neuroscience here (Farr et al., 2016, Journal of Clinical Investigation). On inflammation: semaglutide has been shown to reduce inflammatory cytokines including IL-6 and TNF-alpha in people with obesity, independent of weight loss (Mosenzon et al., 2021, The Lancet Diabetes and Endocrinology). On PCOS specifically: a 2023 meta-analysis by Filippatos et al. in Obesity Reviews found GLP-1 agonists improved menstrual regularity and androgen levels in women with PCOS, though most trials were small and short. On endometriosis: the evidence is thinner. Mouse model studies suggest GLP-1 agonists reduce lesion size, but human clinical trial data is sparse as of mid-2024.

What did they get wrong (or right)?

They got the broad strokes right. GLP-1 receptors genuinely are expressed in reproductive tissue, and the inflammation angle is not invented. The PCOS signal in the literature is real enough that several academic medical centers are now running trials. Credit where it's due.

What the caption overstates, or at least under-qualifies, is the endometriosis claim. Grouping endometriosis and PCOS together as both having "really promising" GLP-1 research implies roughly equivalent evidence bases. They are not equivalent. PCOS research in this area has multiple completed human trials. Endometriosis research is largely preclinical as of 2024. Lumping them together without that distinction misleads patients who might interpret "promising research" as "doctors are already using this for my condition." They mostly are not, at least not for endometriosis.

The caption also never mentions that most GLP-1 benefits in reproductive health observed in trials are in patients with obesity or metabolic dysfunction. Whether lean women with endometriosis benefit is genuinely unknown.

What should you actually know?

GLP-1 receptor agonists are not approved for endometriosis or PCOS treatment. Full stop. If a provider is prescribing semaglutide or tirzepatide specifically for your endometriosis, that is off-label prescribing, and you should ask hard questions about the evidence base they're drawing on.

For PCOS, the story is more nuanced. Several endocrinology guidelines now acknowledge GLP-1 agonists as a reasonable option for PCOS patients who also have obesity or type 2 diabetes, because the metabolic overlap is substantial. The Androgen Excess and PCOS Society published a position statement in 2023 noting the emerging evidence without formally recommending GLP-1 agonists as a PCOS-specific therapy.

The inflammation claim is real but context-dependent. Anti-inflammatory effects observed in clinical trials have generally been in people with significant metabolic disease. Extrapolating that to all women with endometriosis, a condition with a distinct inflammatory mechanism, is a leap the current data does not fully support.

If you have PCOS or endometriosis and are curious about GLP-1 therapy, a conversation with a reproductive endocrinologist is appropriate. A TikTok caption is not a treatment plan.